IPM Take
This is a surveillance story with a political core. A blood test can bring recurrence forward on the clock, but systems must decide what happens next. If ctDNA-positive patients get rapid imaging, specialist review and metastasis-directed treatment, the test becomes a pathway. If not, it becomes anxiety with a receipt.
Executive Summary
The phase III FIND trial, reported this week in the oncology literature, tested ctDNA methylation-guided dynamic surveillance after R0 resection in stage I to III colorectal cancer. The study randomly assigned patients to standard surveillance or a ctDNA-guided strategy, with ctDNA testing every three months for two years and immediate contrast-enhanced CT imaging after a positive result. Among patients who developed recurrence, 48.1% in the ctDNA-guided arm underwent curative-intent metastasis-directed therapy versus 23.6% in the standard surveillance arm. Median time to clinical recurrence was 9.5 months versus 13.4 months, giving a median lead time of 3.9 months. Postrecurrence progression-free survival also favoured the ctDNA-guided group.
Why it matters
- Patients / advocates: Earlier detection is only valuable if it leads to action, not just fear.
- Clinicians: ctDNA-guided surveillance may change how recurrence is detected and triaged after curative-intent surgery.
- Diagnostics / pathology: The operational standard cannot just be assay sensitivity; it must include turnaround, repeat testing and escalation rules.
- Hospitals / providers: Positive ctDNA results require rapid imaging, liver and lung metastasis review, surgical input and treatment coordination.
Cancer surveillance has always had a hidden inequality problem.
Some patients are watched closely. Some are watched loosely. Some know how to move quickly when a scan changes. Others wait until the system calls them back.
The FIND trial puts ctDNA into the middle of that problem. After curative-intent surgery for stage I to III colorectal cancer, patients in the experimental arm received regular ctDNA methylation testing. A positive result triggered immediate imaging, and if imaging was negative, patients stayed under intensified follow-up until the signal cleared or recurrence became visible.
That design matters. The test was not treated as a curiosity. It was tied to an action pathway.
The results are powerful because they do not only show earlier detection. They show more patients getting to potentially curative treatment after recurrence. Among patients who relapsed, nearly half in the ctDNA-guided group received curative-intent metastasis-directed therapy, compared with fewer than a quarter in the standard surveillance group. For liver or lung-confined recurrence, the gap was also substantial.
This is what personalised medicine should be doing: changing timing, not just choosing drugs.
But there is a hard policy warning here. ctDNA-guided surveillance can easily become a two-tier system. Patients treated in well-networked centres may get fast testing, fast CT, fast multidisciplinary review and fast surgery or ablation. Patients in weaker pathways may receive the same positive test and none of the same speed.
That is not precision. That is inequality with better biomarkers.
The next step cannot be “buy the test.” It has to be: define the surveillance protocol, define the imaging trigger, define the referral route, define who pays, and define what counts as a completed intervention. Otherwise, ctDNA will tell systems the truth earlier than they are prepared to act on it.
